Phase 2 N=22 Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
Advanced Cancers · Sarcoma
Primary: Recurrence Free Survival — 13.99 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Desmoplastic Small Round Cell Tumor
Primary: Progression Free Survival (PFS) — NA; NA Months
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 3 N=109 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Sarcoma
Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants
Phase 2 N=48 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Neurofibromatosis Type 1 · Sarcoma
Primary: Number of Participants With Response Rate (Complete Response and Partial Response) — 5; 4; 0; 0 Participants
Phase 3 N=413 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Phase 2 N=44 Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Limited Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: 6 Week Progression Free Survival — 43 percentage of participants
N/A N=1,390 Real-world Study of Dedifferentiated Liposarcoma Patients in China
Dedifferentiated Liposarcoma
Primary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months
Phase 2 N=26 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
Desmoplastic/Nodular Medulloblastoma · Medulloblastoma · Medulloblastoma With Extensive Nodularity
Primary: Progression-free Survival (PFS) — 52.0 percent probability
Phase 2 N=34 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Phase 2 N=62 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Phase 2 N=97 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Soft Tissue Sarcoma
Primary: Progression-free Survival (PFS) (Cohort 1 Only) — 5.0597 months
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 3 N=91 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 2 N=82 Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Phase 2 N=175 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Embryonal Rhabdomyosarcoma
Primary: Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment — 0.9390 Proportion of Participants
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Phase 2 N=92 Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Phase 3 N=642 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Localized Extraskeletal Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor of Bone · Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Primary: Event-Free Survival — 77.64; 78.79 Percent Probability
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 3 N=78 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Phase 3 N=390 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Embryonal Childhood Rhabdomyosarcoma · Embryonal-botryoid Childhood Rhabdomyosarcoma
Primary: Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry — 87; 67 Estimated percentage of participants
Phase 2 N=339 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 15.5; 14.6; 19.3; 18.8 percentage of participants
N/A N=266 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
Sarcoma
Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955
Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Phase 2 N=46 S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
Lung Cancer
Primary: Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical…
Phase 3 N=483 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 6.9; 7.0; 7.4 months
Phase 2 N=72 Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants